Eupraxia Pharmaceuticals Inc.EPRX.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · eupraxiapharma.com
Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biotechnology company focused on developing locally delivered, extended-release drug products for therapeutic areas with high unmet medical need. The company's proprietary Diffusphere technology platform enables development of extended-release formulations designed for localized drug delivery, reducing systemic side effects.
Key ratios
ROA
-39.7%TTM
2025
-39.7%2024
-61.1%2023
-88.4%
ROE
-68.8%TTM
2025
-68.8%2024
-157.3%2023
-715.2%
Recent news
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
Track EPRX.TO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer